Italiano A, Massard C, Bahleda R et al (2008) Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol 19:787–792. https://doi.org/10.1093/annonc/mdm548

Article  PubMed  CAS  Google Scholar 

Horstmann E, McCabe MS, Grochow L et al (2005) Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895–904. https://doi.org/10.1056/NEJMsa042220

Article  PubMed  CAS  Google Scholar 

de Wit R, de Bono J, Sternberg CN et al (2019) Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 381:2506–2518. https://doi.org/10.1056/NEJMoa1911206

Article  PubMed  Google Scholar 

Hadoux J, Walter T, Kanaan C et al (2022) Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study. Endocr Relat Cancer 29:569–580. https://doi.org/10.1530/ERC-22-0102

Article  PubMed  CAS  Google Scholar 

Suzuki E, Ikeda M, Okusaka T et al (2013) A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol 71:1141–1146. https://doi.org/10.1007/s00280-013-2106-0

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909–1919. https://doi.org/10.1056/NEJMoa1414325

Article  PubMed  Google Scholar 

Shitara K, Doi T, Dvorkin M et al (2018) Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 19:1437–1448. https://doi.org/10.1016/S1470-2045(18)30739-3

Article  PubMed  CAS  Google Scholar 

Wang-Gillam A, Li CP, Bodoky G et al (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387:545–557. https://doi.org/10.1016/S0140-6736(15)00986-1

Article  PubMed  CAS  Google Scholar 

Demetri GD, von Mehren M, Jones RL et al (2016) Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 34:786–793. https://doi.org/10.1200/JCO.2015.62.4734

Article  PubMed  CAS  Google Scholar 

Hamanishi J, Takeshima N, Katsumata N et al (2021) Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J Clin Oncol 39:3671–3681. https://doi.org/10.1200/JCO.21.00334

Article  PubMed  PubMed Central  CAS  Google Scholar 

Paulino E, de Melo AC, de Andrade DAP, de Almeida MS (2023) Systemic therapy for advanced cervical cancer: Leveraging the historical threshold of overall survival. Crit Rev Oncol Hematol 183:103925. https://doi.org/10.1016/j.critrevonc.2023.103925

Article  PubMed  Google Scholar 

Makker V, Colombo N, Casado Herráez A et al (2023) Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III study 309/KEYNOTE-775. J Clin Oncol 41:2904–2910. https://doi.org/10.1200/JCO.22.02152

Article  PubMed  PubMed Central  CAS  Google Scholar 

Powles T, Rosenberg JE, Sonpavde GP et al (2021) Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384:1125–1135. https://doi.org/10.1056/NEJMoa2035807

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li DD, Tao ZH, Wang BY et al (2022) Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial. NPJ Breast Cancer 8:110. https://doi.org/10.1038/s41523-022-00462-6

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ida H, Koyama T, Mizuno T et al (2022) Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice. Cancer Sci 113:4300–4310. https://doi.org/10.1111/cas.15586

Article  PubMed  PubMed Central  CAS  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026

Article  PubMed  CAS  Google Scholar 

Bigot F, Castanon E, Baldini C et al (2017) Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer 84:212–218. https://doi.org/10.1016/j.ejca.2017.07.027

Article  PubMed  CAS  Google Scholar 

Arkenau HT, Barriuso J, Olmos D et al (2009) Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 27:2692–2696. https://doi.org/10.1200/JCO.2008.19.5081

Article  PubMed  CAS  Google Scholar 

Kompaniyets L, Freedman DS, Belay B et al (2023) Probability of 5% or greater weight loss or BMI reduction to healthy weight among adults with overweight or obesity. JAMA Netw Open 6:e2327358. https://doi.org/10.1001/jamanetworkopen.2023.27358

Article  PubMed  PubMed Central  Google Scholar 

Kizer NT, Thaker PH, Gao F et al (2011) The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer 117:948–956. https://doi.org/10.1002/cncr.25544

Article  PubMed  Google Scholar 

Renfro LA, Loupakis F, Adams RA et al (2016) Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database. J Clin Oncol 34:144–150. https://doi.org/10.1200/JCO.2015.61.6441

Article  PubMed  CAS  Google Scholar 

Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48:452–458. https://doi.org/10.1038/bmt.2012.244

Article  PubMed  CAS  Google Scholar 

Chihara D, Lin R, Flowers CR et al (2022) Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. Lancet 400:512–521. https://doi.org/10.1016/S0140-6736(22)01390-3

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shimizu T, Sands J, Yoh K et al (2023) First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-pantumor01. J Clin Oncol 41:4678–4687. https://doi.org/10.1200/JCO.23.00059

Article  PubMed  PubMed Central  CAS  Google Scholar 

Meric-Bernstam F, Makker V, Oaknin A et al (2024) Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 42:47–58. https://doi.org/10.1200/JCO.23.02005

Article  PubMed  CAS  Google Scholar 

Walsh RJ, Ong R, Cheo SW et al (2024) Molecular profiling of metastatic breast cancer and target-based therapeutic matching in an Asian tertiary phase I oncology unit. Front Oncol 14:1342346. https://doi.org/10.3389/fonc.2024.1342346

Article  PubMed  PubMed Central  CAS  Google Scholar 

O’Carrigan B, Lim JSJ, Jalil A et al (2018) Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre. Br J Cancer 119:922–927. https://doi.org/10.1038/s41416-018-0290-8

Article  PubMed